Metalloprotease-disintegrin ADAM23 (SVPH3-17) nucleic acids
AssigneeImmunex Corporation
InventorDouglas P. Cerretti
Life of this patent
Estimating the term…
Abstract
The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
Claims24
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule having the sequence of SEQ ID NO:2;
- (b) a nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:4;
- (c) a nucleic acid molecule encoding a fragment of the amino acid sequence of SEQ ID NO:4 having disintegrin activity and comprising amino acids 496 through 599 of SEQ ID NO:4;
- and
- (d) a nucleic acid molecule encoding a fragment of the amino acid sequence of SEQ ID NO:4 having disintegrin activity and comprising amino acids 532 through 586 of SEQ ID NO:4.
An isolated nucleic acid molecule that encodes a fragment of ADAM23 having disintegrin activity, wherein ADAM23 is the polypeptide of SEQ ID NO:4, and wherein the fragment of ADAM23 comprises an amino acid sequence selected from the group consisting of amino acids 496 through 599 of SEQ ID NO:4, and amino acids 532 through 586 of SEQ ID NO:4.
A nucleic acid molecule encoding a fusion protein comprising a fragment of the polypeptide of SEQ ID NO:4 having disintegrin activity and a heterologous polypeptide;
- wherein the fusion protein comprises an amino acid sequence selected from the group consisting of amino acids 496 through 599 of SEQ ID NO:4 and amino acids 532 through 586 of SEQ ID NO:4.
A nucleic acid molecule encoding a fusion protein comprising a fragment of the polypeptide of SEQ ID NO:4 having disintegrin activity and a heterologous polypeptide;
- wherein the fusion protein comprises an amino acid sequence selected from the group consisting of amino acids 496 through 599 of SEQ ID NO:4 and amino acids 532 through 586 of SEQ ID NO:4;
- and wherein the fusion protein comprises a heterologous polypeptide selected from the group consisting of an Fc polypeptide, a peptide linker, and/or a leucine zipper polypeptide.
An isolated nucleic acid molecule that encodes a fragment of ADAM23 having disintegrin activity and further comprises an ADAM23 pro domain amino acid sequence, wherein ADAM23 is the polypeptide of SEQ ID NO:4, and wherein the fragment of ADAM23 comprises an amino acid sequence selected from the group consisting of amino acids 496 through 599 of SEQ ID NO:4 and amino acids 532 through 586 of SEQ ID NO:4;
- and wherein the ADAM23 pro domain amino acid sequence comprises amino acids 58 through 286 of SEQ ID NO:4.
An isolated nucleic acid molecule that encodes a fragment of ADAM23 having disintegrin activity and further comprises an ADAM23 catalytic domain amino acid sequence, wherein ADAM23 is the polypeptide of SEQ ID NO:4, and wherein the fragment of ADAM23 comprises an amino acid sequence selected from the group consisting of amino acids 496 through 599 of SEQ ID NO:4 and amino acids 532 through 586 of SEQ ID NO:4;
- and wherein the ADAM23 catalytic domain amino acid sequence comprises amino acids 286 through 495 of SEQ ID NO:4.
An isolated nucleic acid molecule encoding a polypeptide having disintegrin activity, wherein said polypeptide comprises amino acids 496 through 599 of SEQ ID NO:4.
Dependencies are inferred from the claim text.